Eloxx Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $60.1M
- Price
- $14.88
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.65%
- Volume
- 14.6K
About
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Quick stats
Shares outstanding4.0M
Computed float3.3M
Float / shares80.9%
Cash runway (months)58.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001035354
Websitehttps://www.eloxxpharma.com
AI Summary
AI-generated1/4
minorbullishclinical trial
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
Eloxx Pharmaceuticals dosed the first two patients in the EXACT study, a randomized, placebo-controlled, delayed-start Phase 2b trial evaluating exaluren in 24 patients with nonsense mutation Alport syndrome.
Topline data from the initial 16-week placebo-controlled portion are expected in mid-2027, with the final 32-week readout expected by the end of 2027.
There is currently no FDA-approved therapy addressing the underlying genetic cause of NMAS; roughly 7% of Alport syndrome patients carry these nonsense mutations, which are linked to kidney failure at a mean age of approximately 20 years.
Exaluren holds FDA and European Commission orphan drug designations for Alport syndrome, and a Phase 2 trial in ADPKD is planned; the release cites the company's need for additional capital as a key risk.
Red flags
- Forward-looking statements cite the company's 'need for and ability to obtain additional capital' as a risk factor -- financing/dilution risk before the mid-2027 data readout
- No efficacy or safety data in this release; next meaningful catalyst (topline) is roughly 9 months away